Effective Date **3/15/2024**
Next Review Date… **3/15/2025**
Coverage Policy Number **IP0542**

Faricimab

Table of Contents

Related Coverage Resources

INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This policy supports medical necessity review for faricimab-svoa intravitreal injection (**Vabysmo™**).

Receipt of sample product does not satisfy any criteria requirements for coverage.

Medical Necessity Criteria

Faricimab (Vabysmo) is considered medically necessary when ONE of the following is met:

1. **Diabetic Macular Edema (DME).** Individual meets **ALL** of the following criteria:
    A. Documentation of **ONE** of the following:
        i. Currently receiving Vabysmo
        ii. Failure, contraindication or intolerance to repackaged bevacizumab
        iii. If, in the professional opinion of the prescriber, the safety of using the repackaged bevacizumab or the supplier of the repackaged bevacizumab is of significant concern

B. Medication is administered by, or under the supervision of, an ophthalmologist

Dosing. 6 mg administered by intravitreal injection not more frequent than once every 4 weeks for each eye being treated

2. **Macular Edema Following Retinal Vein Occlusion.** Individual meets **ALL** of the following criteria:
   A. Documentation of **ONE** of the following:
      i. Currently receiving Vabysmo
      ii. Failure, contraindication or intolerance to repackaged bevacizumab
      iii. If, in the professional opinion of the prescriber, the safety of using the repackaged bevacizumab or the supplier of the repackaged bevacizumab is of significant concern
   B. Medication is administered by, or under the supervision of, an ophthalmologist

   Dosing. 6 mg administered by intravitreal injection not more frequent than once every 4 weeks for each eye being treated

3. **Neovascular (Wet) Age-Related Macular Degeneration.** Individual meets **ALL** of the following criteria:
   A. Documentation of **ONE** of the following:
      i. Currently receiving Vabysmo
      ii. Failure, contraindication or intolerance to repackaged bevacizumab
      iii. If, in the professional opinion of the prescriber, the safety of using the repackaged bevacizumab or the supplier of the repackaged bevacizumab is of significant concern
   B. Medication is administered by, or under the supervision of, an ophthalmologist

   Dosing. 6 mg administered by intravitreal injection not more frequent than once every 4 weeks for each eye being treated

---

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Reauthorization Criteria

Continuation of faricimab (Vabysmo) is considered medically necessary for **ALL** covered diagnoses when the above medical necessity criteria are met AND there is documentation of beneficial response.

Authorization Duration

Initial approval duration:
1. Diabetic Macular Edema (DME): up to 12 months
2. Macular Edema Following Retinal Vein Occlusion: up to 6 months
3. Neovascular (Wet) Age-Related Macular Degeneration: up to 12 months

Reauthorization approval duration:
1. Diabetic Macular Edema (DME): up to 12 months
2. Macular Edema Following Retinal Vein Occlusion: up to 6 months
3. Neovascular (Wet) Age-Related Macular Degeneration: up to 12 months

Conditions Not Covered

Any other use is considered experimental, investigational or unproven.

Coding Information

1) This list of codes may not be all-inclusive.
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

HCPCS Codes	Description
J2777	Injection, faricimab-svoa, 0.1 mg (Code effective 10/01/2022)

Background

OVERVIEW
Vabysmo, a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor, is indicated for the following uses:[1]

- **Diabetic macular edema** (DME).
- **Macular edema following retinal vein occlusion** (RVO).
- **Neovascular (wet) age-related macular degeneration** (nAMD).

For the indication of macular edema following RVO, Vabysmo is recommended for use for 6 months.[1] The prescribing information does not note a duration of treatment for DME or nAMD.

Dosing Information
The recommended dosing for each indication is as follows[1]:

- DME: There are two recommended dosage regimens: 1) 6 mg administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days) for at least four doses and then depending on clinical evaluation, dosing interval may be modified by extensions of up to 4 week interval increments or reductions of up to 8 week interval increments; or 2) 6 mg administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days) for the first six doses and then the dosing frequency is every 8 weeks (2 months); some patients may require dosing every 4 weeks after the first four doses.
- Macular edema following RVO: The recommended dose is 6 mg administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days) for 6 months.
- nAMD: The recommended dose is 6 mg administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days) for the first four doses. Thereafter, depending on clinical evaluation, dosing frequency can range from every 4 weeks to every 16 weeks.

References

1. Vabysmo™ intravitreal injection [prescribing information]. South San Francisco, CA: Genentech; October 2023.